OncoMed Provides Update on Tarextumab Phase 2 Pancreatic Cancer ALPINE Trial
Jan 25, 2016 12:30 pm UTC| Business
REDWOOD CITY, Calif., Jan. 25, 2016 -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), a clinical-stage company developing novel anti-cancer stem cell and immuno-oncology therapeutics, announced an update on the Phase 2...
Jan 25, 2016 12:30 pm UTC| Business
FULLERTON, Calif., Jan. 25, 2016 -- To support autism charities and special education, Bourbon Street Bar and Grill’s seventh annual FREE family carnival benefit, ‘Mardi Gras for Autism’ will be held outside Bourbon...
Diffusion Pharmaceuticals Announces Stock Ticker Symbol Change to DFFN
Jan 25, 2016 12:30 pm UTC| Business
CHARLOTTESVILLE, Va., Jan. 25, 2016 -- Diffusion Pharmaceuticals Inc., a clinical stage biotechnology company focused on the development of novel small molecule therapeutics for cancer, today announced that FINRA has...
Jan 25, 2016 12:22 pm UTC| Business
Deerfield Beach, FL, Jan. 25, 2016 -- Zion Research has published a new report titled “mHealth Devices (Glucose Monitors, Blood Pressure Monitors, Cardiac Monitors, Pulse Oximeters, Sleep Apnea Monitors, Multi-parameter...
AlixPartners Boosts China Business with Senior Hire
Jan 25, 2016 12:12 pm UTC| Business
NEW YORK, Jan. 25, 2016 -- AlixPartners, the global business advisory firm, today announced that industry veteran George Geh has joined as a Managing Director in the firm's Shanghai office, effective January 4,...
Jan 25, 2016 12:09 pm UTC| Business
Deerfield Beach, FL, Jan. 25, 2016 -- Zion Research has published a new report titled “Coenzyme Q10 Market for Dietary Supplements, Pharmaceuticals, Cosmetics and Others Applications: Global Industry Perspective,...
ANSYS to Release Fourth Quarter and FY 2015 Earnings on February 25, 2016
Jan 25, 2016 12:09 pm UTC| Business
PITTSBURGH, Jan. 25, 2016 -- ANSYS, Inc. (NASDAQ:ANSS) announced today that the Company expects to release its fourth quarter and FY 2015 earnings on Thursday, February 25, 2016. The Company will hold a conference call...